493 related articles for article (PubMed ID: 29340881)
21. Quantification of circulating plasma cell free DNA fragments in patients with oral cancer and precancer.
Desai A; Kallianpur S; Mani A; Tijare MS; Khan S; Jain M; Mathur V; Ahuja R; Saxena V
Gulf J Oncolog; 2018 May; 1(27):11-17. PubMed ID: 30145546
[TBL] [Abstract][Full Text] [Related]
22. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
Tan G; Chu C; Gui X; Li J; Chen Q
Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
[TBL] [Abstract][Full Text] [Related]
24. Plasma Cell-Free DNA Is a Potential Biomarker for Diagnosis of Calcific Aortic Valve Disease.
Ma W; Zhang W; Liu H; Qian B; Lai R; Yao Z; Wang Y; Yan Y; Yuan Z
Cardiology; 2024; 149(2):155-162. PubMed ID: 37899036
[TBL] [Abstract][Full Text] [Related]
25. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
26. Circulating DNA in Egyptian Women with Breast Cancer.
Ibrahim IH; Kamel MM; Ghareeb M
Asian Pac J Cancer Prev; 2016; 17(6):2989-93. PubMed ID: 27356723
[TBL] [Abstract][Full Text] [Related]
27. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
28. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
Sunami E; Vu AT; Nguyen SL; Giuliano AE; Hoon DS
Ann N Y Acad Sci; 2008 Aug; 1137():171-4. PubMed ID: 18837943
[TBL] [Abstract][Full Text] [Related]
29. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
30. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
31. Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.
Yang J; Cheng L; Zhang J; Chen L; Wang D; Guo X; Ma X
Medicine (Baltimore); 2018 Jul; 97(28):e11417. PubMed ID: 29995790
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
Miao Y; Fan Y; Zhang L; Ma T; Li R
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
[TBL] [Abstract][Full Text] [Related]
33. The integrity of cfDNA in follicular fluid and spent medium from embryo culture is associated with embryo grade in patients undergoing in vitro fertilization.
Pan M; Shi H; Liu Z; Dong J; Cai L; Ge Q
J Assist Reprod Genet; 2021 Dec; 38(12):3113-3124. PubMed ID: 34820723
[TBL] [Abstract][Full Text] [Related]
34. Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer.
Waki K; Yokomizo K; Yoshiyama K; Takamori S; Komatsu N; Yamada A
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):176-182. PubMed ID: 33541161
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
[TBL] [Abstract][Full Text] [Related]
36. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
37. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
38. High Cell-Free DNA Integrity Is Associated with Poor Breast Cancer Survival.
Lamminaho M; Kujala J; Peltonen H; Tengström M; Kosma VM; Mannermaa A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572906
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
[TBL] [Abstract][Full Text] [Related]
40. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]